Corvus Jumps On COVID-19 Drug Bandwagon Corvus Pharmaceuticals Inc. (CRVS) has initiated a phase I study of CPI-006, which represents a novel immunotherapy approach, in patients with COVID-19. CRVS touched a new 52-week high of $6.88 in intraday trading on Tuesday, before closing at $4.95, up 80.84%. (RTTNews) - Today's Daily Dose brings you news about the pipeline progress of Annovis Bio, new entrants in the COVID-19 drug development space, Livongo Health's upbeat preliminary Q2 revenue, Regeneron's BARDA contract, Novavax stock price touching new high and Mallinckrodt's near-term regulatory catalyst.